Swiss National Bank
BDTX icon

Swiss National Bank’s Black Diamond Therapeutics BDTX Stock Holding History

Swiss National Bank’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-47,600
Closed -$403K – 2724
2021
Q3 		$403K Hold
47,600
– – ﹤0.01% 2601
2021
Q2 		$580K Buy
47,600
+23,200
+95% +$459K ﹤0.01% 2612
2021
Q1 		$592K Hold
24,400
– – ﹤0.01% 2444
2020
Q4 		$782K Buy
24,400
+4,400
+22% +$145K ﹤0.01% 2383
2020
Q3 		$605K Hold
20,000
– – ﹤0.01% 2318
2020
Q2 		$843K Buy
+20,000
New +$736K ﹤0.01% 2200

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Swiss National Bank's BDTX Position: Q4 2021 in Review

Swiss National Bank sold out of Black Diamond Therapeutics (BDTX) in Q4 2021, closing a stake of 47,600 shares — an estimated $403K sold.

Swiss National Bank first reported a position in BDTX in Q2 2020 and held it in 6 quarters. The position peaked at $843K in Q2 2020. 95 funds tracked by Wall St. Rank hold BDTX as of Q4 2021.

  • Swiss National Bank reported no remaining Black Diamond Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Swiss National Bank sold 47,600 Black Diamond Therapeutics shares in Q4 2021, an estimated $403K.
  • Swiss National Bank first reported a position in Black Diamond Therapeutics in Q2 2020 and held it in 6 quarters.
  • Swiss National Bank's Black Diamond Therapeutics position peaked at $843K in Q2 2020.
  • 95 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2021.

Based on Swiss National Bank's 13F filing for Q4 2021, filed 8 Feb 2022.